Antinuclear antibodies in patients with SLE stratified according to sex and onset of the disease
| Total | Total N (%) | Sex | Onset of the disease | ||||
| Women, n (%) | Men, n (%) | P value | Early onset <50 years, n (%) | Late onset 50 years, n (%) | P value | ||
| Nucleosome | 31 (11.2) | 30 (12.0) | 1 (3.7) | 0.406 | 18 (10.5) | 13 (12.1) | 0.406 |
| dsDNA (+) | 204 (71.3) | 183 (70.9) | 21 (75.0) | 0.651 | 135 (77.1) | 69 (62.2) | 0.006 |
| Sm (+) | 35 (12.0) | 32 (12.2) | 3 (10.7) | 0.822 | 22 (12.4) | 13 (11.5) | 0.827 |
| RNP (+) | 30 (10.6) | 28 (10.6) | 2 (7.1) | 0.801 | 22 (12.3) | 8 (7.1) | 0.257 |
| Ro (+) | 108 (37) | 103 (39.0) | 5 (17.9) | 0.027 | 61 (34.1) | 47 (41.6) | 0.195 |
| La (+) | 27 (9.2) | 27 (10.2) | – | 0.076 | 13 (7.3) | 14 (12.4) | 0.141 |
Data are expressed as frequency and percentage.
Bold values denote statistical significance (p<0.05).
dsDNA, double-stranded DNA; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus; Sm, Smith.